Adjusted for cell proportions: TRUE PR **PNR** PR - PNR **IFX IFX IFX** enriched in T cells (I) (LI.M7.0) -T cell activation (I) (LI.M7.1) -T cell surface signature (LI.S0) -T cell activation (II) (LI.M7.3) enriched in NK cells (I) (LI.M7.2) plasma cells & B cells, immunoglobulins (LI.M156.0) -T cell differentiation (Th2) (LI.M19) enriched in B cells (I) (LI.M47.0) -T cell activation and signaling (LI.M5.1) -B cell surface signature (LI.S2) enriched in B cells (II) (LI.M47.1) plasma cells, immunoglobulins (LI.M156.1) lymphocyte generic cluster (LI.M60) enriched in B cells (III) (LI.M47.2) -Gene module enriched in B cells (VI) (LI.M69) enriched in antigen presentation (I) (LI.M71) -MHC-TLR7-TLR8 cluster (LI.M146) -TBA (LI.M105) type I interferon response (LI.M127) enriched in antigen presentation (II) (LI.M95.0) antiviral IFN signature (LI.M75) enriched in neutrophils (I) (LI.M37.1) platelet activation (II) (LI.M32.1) enriched in myeloid cells and monocytes (LI.M81) cell cycle and transcription (LI.M4.0) enriched in monocytes (IV) (LI.M118.0) -Monocyte surface signature (LI.S4) -TLR and inflammatory signaling (LI.M16) immune activation - generic cluster (LI.M37.0) enriched in monocytes (II) (LI.M11.0) -40 -log10(FDR)

Direction of effect

Down at week 14

Not significant

Up at week 14

Effect size (AUC)

0.5

0.7

0.9